STALICLA’s Post

Sometimes in your career, there comes a point where your gut says you must get involved, as the stakes are much bigger than any one individual can handle! Developing drugs for neurodevelopmental disorders is one such task ! Delighted to be joining the Board of Stalicla, SA and their mission to redefine a path for developing drugs for neurodevelopmental disorders, such as autism spectrum disorder.  When both clinical diagnosis and the measurement of response to a medication are based on behavior, how do we fit biology (which is fundamental to any drug development) into the equation? As the heterogeneity in ASD continue to grow, drug development will get even harder, unless we can understand patient stratification based on biology.  How do we make drug development precise?  Can multi-omics and AI help? How do you convert subjective assessments into objective measurements? It was a casual conversation with very impressive CEO, Lynn Durham, and her team’s passion to decode the biological basis for behavior in stratified cohorts of patients that got me to this point.  Their recently published Phase 1b data, I believe, is transformational in the field of autism spectrum disorder where rational drug development is long overdue! https://lnkd.in/eU6zeHAx Lot of work ahead, but the foundation is built.  Let’s take on neurodevelopment ! #stalicla # precision medicine #autism #neurodevelopment # neuropsychiatry #TiE Boston #Neurology

We thank Forbes for highlighting Beacon among the burgeoning scene of neurotech and AI biomarker companies working hard to bring precision medicine approaches to Alzheimer's disease! Beacon is actively investigating epileptiform activity and sleep dysfunction in patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) to determine possible associations between EEG biomarkers and clinical outcomes. Reach out at https://lnkd.in/errYwFaE to learn more about how we can work together to leverage our clinico-EEG database of 75,000+ patients to drive insights in MCI and AD, along with other neurological and psychiatric conditions. #Alzheimers #MCI #biomarkers #endpoints #EEG #PSG #clinicaltrials https://lnkd.in/eKGCU3rM

A need for personalized medicine in CNS conditions Clinically, CNS disorders exhibit significant heterogeneity. Unfortunately, neurological clinical trials often overlook these variabilities, resulting in costly trial failures. The utilization of emerging omics technologies and datasets has the potential to enhance the identification of biomarkers for patient stratification. In this sense, it is imperative to study the diversity of genetic ancestries and the environmental exposures of research participants. This will definitely impact the healthcare systems. The original article was published in Sci Trans Med. #genetics #genomics #precisionmedicine #genomicmedicine #brain #neurology #neurodegeneration #neurioscience #parkinson #alzheimer #cns #raredisease #als #neurodevelopment #ftd #schizophrenia #psychosis #psychiatry #biomarkers #omics #healthcare #metabolomics #clinicaltrials #clinicalresearch #environment #biotechnology #innovation #research #omics #science #sciencecommunication

"CONCLUSIONS Hypermetabolism is likely pathogenic in depression, with its magnitude in direct proportion to the severity of depressive symptoms. It is brain-wide, with disproportionate increases in cortical and subcortical attentional networks, particularly in women and older patients. Future Cerebral Blood Flow (CBF) studies should be sufficiently large to permit assessment of regional flow without whole brain Cerebral Blood Flow (wbCBF) normalization, and they should include participants with a full range of clinical presentations to ensure findings generalize to real-world patients. SSRIs are associated with lower regional Cerebral Blood Flow (rCBF), which may account in part for their therapeutic effects. Hypermetabolism may be a reasonable target for novel therapeutics in MDD" https://lnkd.in/g8Yk4mVk

𝗗𝗮𝗶𝗹𝘆 𝗡𝗲𝘂𝗿𝗼-𝗯𝗶𝘁𝗲𝘀 🧠: 🌟 Exciting Times Ahead in Neurological Disease Research! 🌟 The second half of 2024 promises ground-breaking developments in neuropsychiatric and neurodegenerative disease research. 𝗛𝗲𝗿𝗲 𝗮𝗿𝗲 𝗳𝗶𝘃𝗲 𝗸𝗲𝘆 𝗱𝗮𝘁𝗮 𝗿𝗲𝗮𝗱𝗼𝘂𝘁𝘀 𝘁𝗼 𝘄𝗮𝘁𝗰𝗵: 🥊Athira Pharma’s Fosgonimeton (#Alzheimer’sDisease): A novel treatment focusing on the HGF/MET system to enhance #neuroprotection and reduce #inflammation. Phase II/III trial results are expected soon! 💭AbbVie/Cerevel Therapeutics’s Emraclidine (#Schizophrenia): Following a $9B investment, Phase II trials aim to show rapid symptom improvement. Can emraclidine outpace competitors in the schizophrenia treatment race? ☔Neumora Therapeutics’ Navacaprant (#MajorDepressiveDisorder): This Kappa-opioid receptor antagonist offers a new approach to #MDD treatment. Phase III data expected to highlight its potential as a first-in-class therapy. ⚕️Amylyx Pharmaceuticals’s AMX003 (#WolframSyndrome): Following challenges with #ALS treatment, Amylyx is targeting this rare, multi-organ disease with promising Phase II interim results showing improved pancreatic function. 🧠Vigil Neuroscience’s Iluzanebart (ALSP): Aiming to treat the rare, inherited #ALSP, this Phase II trial explores a novel mechanism targeting microglial dysfunction. Could it be the breakthrough needed for this untreatable condition? Stay tuned for these pivotal updates that could transform patient care! #NeuroScience #ClinicalResearch #Pharma #Biotech #Alzheimers #Schizophrenia #Depression #RareDiseases https://lnkd.in/ePWKgnMr

The BRAIN Foundation Industry Spotlight aims to inform and bring to public awareness companies that are developing novel solutions for #autism and related disorders: #biomarkers precision diagnostics or new and ground-breaking treatments and therapies.   This week’s spotlight is on Eumentis Therapeutics Inc., a privately held clinical stage pharmaceutical company founded in 2019 with the mission to develop novel #therapies to improve the quality of life of patients suffering from central nervous system disorders. EuMentis is evaluating #neuropsychiatric conditions that involve glutamate or dopamine imbalance for low-trapping NMDA antagonists, EM-221, or other novel compounds derived from its platforms to treat symptoms of pediatric neuropsychiatric disorders such as Tourette Syndrome and #AutismSpectrumDisorder. To find out more visit https://lnkd.in/eAeGaMjV EUMENTIS TEAM Mark Tepper, Ph.D., President & CEO Randall D. Marshall MD, Chief Medical Officer James Larrick, MD, PhD Chief Scientific Officer Catherine Moncad Head of Regulatory Services (TMC) Jo Emmett Head of Clinical Operations Xiaoming Zhang, PhD Head of CMC EUMENTIS SCIENTIFIC ADVISORS Stuart Lipton, MD, PhD (Scientific Founder) Professor, Scripps Research Institute and UC San Diego, La Jolla Jeffrey Neul, MD, PhD Professor, Vanderbilt University School of Medicine, Nashville, TN Stephen Traynelis, PhD Professor, Dept of Pharmacology, Emory University School of Medicine, Atlanta, GA Gagan Joshi, MD Associate Professor, Psychiatry, Harvard Medical School; Director, Autism Spectrum Disorder Program, Mass General Hospital Donald Gilbert, MD Professor, University of Cincinnati, Cincinnati Children's Hospital Keith Coffman, MD Associate Professor, Children’s Mercy Hospital #neuroscience #pharmaceuticals #science #drugdevelopment #clinicaltrials #tourettesyndrome #precisionmedicine

Thank you for highlighting our foundational paper on Precision Pharmacology. To take this to the next level, we recently described the architecture and fundamentals of Precision Medicine for neurological and psychiatric diseases in the Cell Press journal Trends in Neurosciences. Highlights included the role of biomarkers in multi-omics profiling, systems medicine approaches, digital tool uses in early detection, big data and artificial intelligence opportunities and challenges. Read the full issue here: bit.ly/3CKVcIe Cell Press #precisionmedicine #precisionhealth #genomicmedicine #multiomics #biomarkers #neurologicaldisorders #alzheimers #pharmacology #artificialintelligence #bigdata #digitalhealth

Bristol Myers Squibb has announced a $14 billion acquisition of Karuna Therapeutics, marking a significant shift in its focus towards #neuroscience. This move centers on #KarXT (#xanomeline-trospium), Karuna's novel #antipsychotic targeting #schizophrenia and #Alzheimer's disease psychosis. The deal underscores a growing industry trend towards developing #psychiatric and #neurologicaldrugs, reflecting the urgent need for innovative treatments in mental health. https://lnkd.in/dvRjtgqq

After a dynamic first half of 2024, the upcoming months are set to bring significant developments in neuropsychiatric and neurodegenerative disease research. Key data readouts are anticipated across Alzheimer’s, schizophrenia, depression, and rare diseases. Highlights include: 🧠 Athira Pharma’s Fosgonimeton for Alzheimer’s, showing promise in Phase II/III trials. 🧠 AbbVie/Cerevel Therapeutics’s Emraclidine for schizophrenia, with Phase II results expected soon. 🧠 Neumora Therapeutics’ Navacaprant for major depressive disorder, entering Phase III. 🧠 Amylyx Pharmaceuticals’s AMX0035 for Wolfram syndrome, following ALS treatment challenges. 🧠 Vigil Neuroscience’s Iluzanebart for ALSP, a rare neurological disease. Stay tuned for these pivotal updates that could reshape the treatment landscape for these critical conditions. #Neuroscience #ClinicalResearch #Alzheimers #Schizophrenia #Depression #RareDiseases #Biotech #Pharma #HealthcareInnovation https://lnkd.in/ejgBG4F9

Episode 5 Preview: Dr Leon Henderson-MacLennan, MD, FACP, medical advisor and co-founder of inThought Research, gives his external perspective of Arialys Therapeutics, Inc. ART-5803 for autoimmune encephalitis and its potential for expansion into a subset of other neuropsychiatric conditions -- which may include schizophrenia, bipolar, severe depression & epilepsy. Listen to the episode here ⏯️ 🎧: https://lnkd.in/er76zuH3